Trials / Not Yet Recruiting
Not Yet RecruitingNCT07106125
Antibiotics for Kidney Transplant Recipients
Trial of Antibiotic Strategies for Kidney Transplant Recipients
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 29 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Conditions
- Kidney Transplant
- Urinary Tract Infection(UTI)
- Antibiotic Prophylaxis
- Remote Patient Monitoring
- Feasibility Pilot Study
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trimethoprim-Sulfamethoxazole (TMP-SMX) | Kidney transplant recipients will continue to take TMP-SMX daily from months 6-12 after transplant |
| OTHER | Usual Care | Participants will take a placebo from months 6-12 after transplant and continue to receive all standard usual care related to their kidney transplant status |
Timeline
- Start date
- 2026-11-01
- Primary completion
- 2028-12-01
- Completion
- 2029-01-01
- First posted
- 2025-08-06
- Last updated
- 2025-10-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07106125. Inclusion in this directory is not an endorsement.